Assessing the exposure risk and impacts of pharmaceuticals in the environment on individuals and ecosystems. by Arnold, KE et al.
rsbl.royalsocietypublishing.orgMeeting report
Cite this article: Arnold KE, Boxall ABA,
Brown AR, Cuthbert RJ, Gaw S, Hutchinson TH,
Jobling S, Madden JC, Metcalfe CD, Naidoo V,
Shore RF, Smits JE, Taggart MA, Thompson
HM. 2013 Assessing the exposure risk and
impacts of pharmaceuticals in the environment
on individuals and ecosystems. Biol Lett 9:
20130492.
http://dx.doi.org/10.1098/rsbl.2013.0492Received: 28 May 2013





vultures, risk prediction, bioindicatorsAuthor for correspondence:
Kathryn E. Arnold
e-mail: kathryn.arnold@york.ac.uk& 2013 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.Global change biology
Assessing the exposure risk and impacts
of pharmaceuticals in the environment
on individuals and ecosystems
Kathryn E. Arnold1, Alistair B. A. Boxall1, A. Ross Brown2,3, Richard
J. Cuthbert4, Sally Gaw5, Thomas H. Hutchinson6, Susan Jobling7,
Judith C. Madden8, Chris D. Metcalfe9, Vinny Naidoo10, Richard F. Shore11,
Judit E. Smits12, Mark A. Taggart13 and Helen M. Thompson14
1Environment Department, University of York, York, UK
2AstraZeneca, Brixham Environmental Laboratory, Brixham, UK
3College of Life and Environmental Sciences, University of Exeter, Exeter, UK
4Royal Society for the Protection of Birds, Sandy, UK
5Department of Chemistry, University of Canterbury, Christchurch, New Zealand
6Centre for Environment, Fisheries and Aquaculture Science, Weymouth, UK
7Institute for the Environment, Brunel University, Uxbridge, UK
8School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK
9Institute for Watershed Science, Trent University, Peterborough, Canada
10Biomedical Research Centre, University of Pretoria, Pretoria, South Africa
11Centre for Ecology and Hydrology, Lancaster, UK
12Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada
13University of the Highlands and Islands, Thurso, UK
14Food and Environment Research Agency, Sand Hutton, UK
The use of human and veterinary pharmaceuticals is increasing. Over the past
decade, there has been a proliferation of research into potential environmental
impacts of pharmaceuticals in the environment. A Royal Society-supported
seminar brought together experts from diverse scientific fields to discuss
the risks posed by pharmaceuticals to wildlife. Recent analytical advances
have revealed that pharmaceuticals are entering habitats via water, sewage,
manure and animal carcases, and dispersing through food chains. Pharmaceu-
ticals are designed to alter physiology at low doses and so can be particularly
potent contaminants. The near extinction of Asian vultures following exposure
to diclofenac is the key example where exposure to a pharmaceutical caused a
population-level impact on non-target wildlife. However, more subtle changes
to behaviour and physiology are rarely studied and poorly understood. Grand
challenges for the future includedevelopingmore realistic exposure assessments
forwildlife, assessing the impacts ofmixtures ofpharmaceuticals in combination
withotherenvironmental stressors andestimating the risks frompharmaceutical
manufacturing and usage in developing countries. We concluded that an inte-
gration of diverse approaches is required to predict ‘unexpected’ risks;
specifically, ecologically relevant, often long-term and non-lethal, consequences
of pharmaceuticals in the environment for wildlife and ecosystems.
1. Introduction
The continued expansion of the human population is leading to escalating demand
for resources, including human and veterinary pharmaceuticals. Pressures are
exerted by increasingly intensive agriculture and exacerbated by rising human
longevity and obesity, leading to more health problems [1]. With this comes




2subsequently excreted. While the health benefits of medication
are fundamentally important, it is only in the past decade that
the potential environmental impacts of pharmaceuticals have
begun to be considered in detail [2,3]. At a recent Royal Society-
funded Research Fellow International Scientific Seminar, experts
from diverse research fields discussed the risks to wildlife posed
by pharmaceuticals in the environment. Our conclusions have
policyrelevance to theongoingdebate in theEUover theprospect
of environmental quality standards for specific pharmaceuticals.
Pharmaceuticals are a potentially potent group of chemical
contaminants, because theyaredesigned tohavebiological effects
at low concentrations. Given evolutionary conservation across
vertebrate taxa, both human and veterinary pharmaceuticals
may be predicted to act on many non-target species [4]. It is
also now emerging that pharmaceuticals and their biotransform-
ation products are present in a range of habitats, some can
bioaccumulate and may have significant, but largely unstudied,
consequences for individuals, populations and ecosystems [2,3].2. 17a-ethinyloestradiol and non-steroidal anti-
inflammatory drugs: lessons learned and
wider implications for wildlife
The two clearest cases of pharmaceuticals affecting wild-
life to date involve 17b-oestradiol (E2) and the synthetic
oestrogen 17a-ethinyloestradiol (EE2), and the non-steroidal
anti-inflammatory drug (NSAID), diclofenac [5,6]. There is
now convincing evidence of the feminization of male fish
downstream of sewage treatment works (STWs) discharging
complex effluent, which includes E2 and EE2 from the contra-
ceptive pill and hormone-replacement therapies [5]. While
deleterious effects have been found on reproductive traits of
individuals, Susan Jobling (Brunel University) showed that
individual male reproductive success in breeding groups
declines with increased feminization, but intersex fish can still
breed [7]. Jobling’s group has estimated modest increases in
oestrogen equivalents in the UK’s waterways over the time
period to 2050 [8]. Thus, it seems pertinent to ascertain public
opinion regarding intersex fish in European rivers and willing-
ness to pay for water treatments that remove harmful levels of
pharmaceuticals and other micro-pollutants from effluents.
Three Asian vulture species are now critically endangered
because of acute toxicity following consumption of the carcases
of diclofenac-treated livestock. Richard Cuthbert’s (RSPB)work
has been instrumental in banning the sale of diclofenac for
veterinary use and promoting the sale of a vulture-safe alterna-
tive [6]. Consequently, there is an indication that endangered
vulture populations are starting to recover, although numbers
remain very low (less than 1% of previous levels) across South
Asia. However, residues of diclofenac and other potentially
toxic NSAIDs are still being detected in dead vultures.3. Exposure pathways for wildlife
Recent improvements in analytical technologies haveenabled the
detection and quantification of pharmaceuticals in environmen-
tal matrices, including surface waters and soil [3]. However,
efforts need to be targeted andmeasured concentrations presen-
ted within a risk-based context. Exposure risk can be estimated
from prescription and sales figures, then refined based on the
excretion of un-metabolized ‘parent compounds’ or bioactivemetabolites, persistence in the environment and potential to
bioaccumulate in food chains. Such an approach has been used
by Chris Metcalfe (Trent University) to predict environmental
concentrations of antidepressants. Long-term monitoring of
pharmaceuticals in rivers and lakes confirmed the presence of
antidepressants and other pharmaceuticals in plumes around
STWoutflows [9].Wild fish cagedwithin these plumes exhibited
significant changes in a range of biomarkers, but consequences
for individual fitness and population persistence are unknown.
Monitoring exposure to pharmaceuticals in terrestrial
ecosystems is less well developed than in freshwater, but trans-
ferable techniques have been used to assess exposure risk to
plant protection products on farmland [10]. Via radio-tracking,
Helen Thompson (FERA) has mapped how wild birds and
mammals disperse around contaminated resources at the land-
scape scale, which could also be used to record the movements
of terrestrial vertebrates on STWs or sewage sludge fertilized
fields, for example. At the national level, Richard Shore
(CEH) suggested that current wildlife monitoring schemes,
for example, the Predatory Bird Monitoring Scheme (http://
pbms.ceh.ac.uk/), could be adapted to include surveillance
for pharmaceutical exposure in addition to other contaminants
[11]. Temporal and spatial trends in pharmaceutical exposure
could therefore potentially be traced.
As with terrestrial habitats, there is a lack of data on
pharmaceutical exposures for the marine environment, high-
lighted by Sally Gaw (University of Canterbury), despite it
being a major receptor for wastewater due to increasing
human habitation of coastal areas and more intensive use
of pharmaceuticals in aquaculture.4. Uptake and fate of pharmaceuticals
in food webs
In contaminated environments, uptake of pharmaceuticals by
invertebrates was shown by Alistair Boxall (University of
York) to vary depending on the chemistry of the environ-
mental matrix and species’ mode of feeding, thus effects
can be difficult to predict [12]. Similarly, in terrestrial ver-
tebrates, understanding consequences of group versus
solitary feeding, or responses to novel food types, is impor-
tant when designing captive experiments to calculate a
realistic uptake rate [10]. Extending his work on the uptake
and fate of NSAIDs in Asian vultures [6,13], Mark Taggart
(University of the Highlands and Islands) is also analysing
vulture and livestock samples with the aim of assessing the
true risk of veterinary antibiotics to scavenging birds in
Spain, a stronghold for vultures in Europe. Understanding
the ecology of susceptible, exposed animals is vital.5. Behaviour of pharmaceuticals
Risk assessment in the twenty-first century faces many chal-
lenges, including the growing numbers of compounds in
circulation, while avoiding excessive use of animal testing.
Thomas Hutchinson (CEFAS) described recent work on
developing the OECD’s Adverse Outcome Pathway (AOP)
approach to prioritize species selection for laboratory
research and field monitoring; it uses six levels of information
ranging from the chemical properties of a toxicant through to




3pharmaceuticals, this AOP approach can facilitate read-across
between chemicals with similar modes of action across
diverse taxa. This can increase the power of such models to
predict pharmaceutical effects on wildlife [4].
JudithMadden (LJMU)demonstrated theuse and limitations
of in silico tools for predicting ecotoxicity of pharmaceuticals,
including predictions based on simple physico-chemical pro-
perties, as well as tools for grouping compounds into
categories to allow for read-across. Categories can be formed
using profilers for relevant interactions such as DNA or oestro-
gen receptor binding [15]. While models are also available for
uptake and metabolism, understanding inter- and intraspecies
variation is fundamental to predicting toxicity. Experiments by
Vinny Naidoo (University of Pretoria) have shown that Gyps
and other vulture species have an unusual metabolism with
respect to NSAIDs [16]; they are suggested to be CYP 2C9
deficient or diminished, as are cats, which are also highly sensi-
tive to NSAIDs and so may provide a pharmacokinetic model
for vultures.6. Effects of pharmaceuticals on wildlife
The paucity of studies on the effects of pharmaceuticals on
non-model, particularly terrestrial, species was further high-
lighted by Judit Smits (University of Calgary). Essentially,
we now need further development of non-lethal assays or
biomarkers of subclinical toxicity following exposure to con-
taminants, for example, biotransformation enzymes and
hormones [17]. Key features of an ideal sentinel for pharma-
ceutical risk in the wild include natural risk of exposure,
toleration of human disturbance and relevance to the food
web of interest. One such species is the European starling
Sturnus vulgaris, which commonly feeds on pharmaceutical-
contaminated invertebrates living on STWs. The species is
robust to capture and captivity and forages on invertebrates,
a potentially important but unstudied exposure route. Kathryn
Arnold (University of York) found that long-term exposure to
an environmentally relevant dosage of fluoxetine (Prozac), a
commonly used antidepressant, altered physiology, behaviour
andmass balance in starlings. While behaviours are non-lethal
and ecologically relevant endpoints tomeasure in such studies,
they can be challenging to analyse and interpret because of the
high degree of individual variability [18].
Standardized laboratory tests and endpoints are requi-
red in order to ensure the reliability and repeatability of
ecotoxicological studies. Exposure conditions and test organ-
isms need careful consideration, as, for example, there may be
significant inter- and intraspecies variation in sensitivity,
requiring the use of additional safety factors. Although
many studies claim to use outbred strains, which areconsidered more representative of wild populations, these
claims are rarely supported by pedigree or genetic evalu-
ation. Ross Brown (AstraZeneca and University of Exeter)
has shown that inbred family lines of zebrafish can differ sig-
nificantly in their physiological and developmental responses
to pharmaceuticals, compared with outbred wild-type family
lines [19].7. Grand challenges for research, regulation and
policy development
We identified several grand challenges for researchers in this
field including; firstly, realistic assessments of exposure risks
to pharmaceuticals, which are missing for most species,
should account for the diversity and abundance of pharmaceu-
ticals in environmental matrices, dispersal data for animals in
contaminated landscapes and processes affecting uptake via
diet or other routes. Assessments need to be future-proofed
against increasing water scarcity and recycling of raw sewage,
wastewater and application of sewage sludge in agriculture.
Secondly, current prospective risk assessments are based
on individuals exposed to a single pharmaceutical under rela-
tively benign laboratory conditions. In reality, animals are
exposed to cocktails of chemicals, including pharmaceuticals
and multiple environmental stressors, which can interact
synergistically, additively or antagonistically [3]. Pharmaceu-
tical impacts, where they occur, need to be distinguished
from variation in fitness-related traits due to natural or
anthropogenically mediated fluctuations in food availability,
parasitism, etc.
Thirdly, for assessing pharmaceutical risks to wildlife
globally, we need to focus on the developing world, where
pharmaceutical production and consumption is rapidly increas-
ing. With little or no treatment of some manufacturing
discharges or municipal and agricultural waste streams con-
taining human and veterinary pharmaceuticals, risks to
wildlife and humans are predicted to be high, but remain vir-
tually unassessed [20,21]. Such scientific research could
support future international development policies.
Populations of many species living in human-altered
landscapes are declining for reasons that often cannot be
fully explained. Therefore, we believe that diverse approaches
used by academic researchers, industry risk assessors and
regulators need to be better integrated to assess current and
future risks from pharmaceuticals in the environment.
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